ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

SNDZ Sunridge International Inc (CE)

0.0001
0.00 (0.00%)
03 Feb 2025 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Sunridge International Inc (CE) USOTC:SNDZ OTCMarkets Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.0001 0.00 00:00:00

Sunridge Middle East Distributor to Begin Clinical Trials Necessary for Reimbursement

08/12/2010 2:00pm

PR Newswire (US)


Sunridge (CE) (USOTC:SNDZ)
Historical Stock Chart


From Feb 2020 to Feb 2025

Click Here for more Sunridge (CE) Charts.

FOUNTAIN HILLS, Ariz., Dec. 8, 2010 /PRNewswire-FirstCall/ -- Sunridge International (OTC Bulletin Board: SNDZ), announced today that Ameco Medical is preparing to start the short term clinical trials needed for reimbursement approval.  

Ameco Medical Equipment L.L.C., Sunridge's exclusive distributor for several Middle Eastern countries, has invited Dr. Leo D. Bores, Sunridge's medical consultant, to attend the start of their clinical trials.  Dr. Bores would be traveling to multiple countries in the Middle East to work with key opinion leaders at some of the largest hospitals and clinics in the region.  The purpose of the study will be to achieve reimbursement approval for the PNT procedure throughout the area.  

Sunridge International's CEO, G. Richard Smith states, "We strive to have a close working relationship with our distributors so that we can assist them when needed in order to obtain success.  Once reimbursement is established, the tens of thousands of glaucoma sufferers can avail themselves of this non-invasive treatment."

Glaucoma is the second leading cause of blindness, affecting over 70 million people worldwide. PNT has been proven (through studies completed over the last 10 yrs) to be a safe, effective, non-invasive and cost effective alternative for treatment for glaucoma and ocular hypertension. The 2-minute treatment has been developed, patented, and distributed by Sunridge International, wholly owned subsidiary, Ophthalmic International www.oi-pnt.com.

   CONTACT:

   Jeff Smith, Sunridge International

   T:  +1-480-837-6165

   e-mail: info@sunridgeint.com



   MEDIA:

   Victor Webb, Marston Webb International

   T: (212) 684-6601

   e-mail: marwebint@cs.com





SOURCE Sunridge International

Copyright 2010 PR Newswire

1 Year Sunridge (CE) Chart

1 Year Sunridge (CE) Chart

1 Month Sunridge (CE) Chart

1 Month Sunridge (CE) Chart

Your Recent History

Delayed Upgrade Clock